Open access · CC-BY
via OpenAlex
Extracellular vesicles in longEVity medicines
Shunhua Ding, Qingyu Lei, Wojciech Chrzanowski
Biomedical Materials Science · 2026
Genomic instability
Epigenetic alterations
Mitochondrial dysfunction
Cellular senescence
Stem-cell exhaustion
Altered intercellular communication
Chronic inflammation
Plasma dilution / young plasma
Human
Mouse
Abstract
As the global ageing population expands, there is an increasing demand for interventions that extend healthspan(definition) and lifespan. Extracellular vesicles (EVs), the mediators of intercellular communication, are promising therapeutic candidates for their systemic rejuvenating effects. The diverse molecular payloads and multiple signalling modes enable the modulation of several ageing pathways across different cell types. In this perspective, we critically evaluate the rejuvenating potential of young plasma-derived small EVs (sEVs) prompted by the landmark study by Chen et al. within the framework of the twelve hallmarks of ageing. Evidence indicated that young sEVs improve mitochondrial function, reduce cellular senescence(definition), elevate stem cell activity, and restore physiological performance. These improvements occurred across multiple organ systems, including brain, muscle, heart, bone, and reproductive tissues, extending median lifespan by ~ 12% in aged mice. Mechanistically, these effects are linked to the enrichment of miRNAs that converge on the PGC-1α–mitochondrial axis. While this research provides bidirectional proof-of-concept for reversing decline, we critically assess current limitations, including unexamined hallmarks of ageing, such as genomic instability, epigenetic alterations, and chronic inflammation. Furthermore, significant gaps remain regarding durability after treatment cessation, alongside challenges related to manufacturing, standardisation, and regulatory translation. This work supports EVs as a distinct class of multi-specific biological therapeutics with the potential to reshape longevity medicine. It pinpoints key gaps that must be addressed to enable safe and effective clinical translation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s44495-026-00006-1
- Canonical
- link ↗
- Fetched
- 2026-10-05 MST
Cite this
APA
Ding, S., Lei, Q., & Chrzanowski, W. (2026). Extracellular vesicles in longEVity medicines. <em>Biomedical Materials Science</em>. https://doi.org/10.1186/s44495-026-00006-1
Vancouver
Ding S, Lei Q, Chrzanowski W. Extracellular vesicles in longEVity medicines. Biomedical Materials Science. 2026. doi:10.1186/s44495-026-00006-1.
BibTeX
@article{shunhua2026Extrac,
title = {Extracellular vesicles in longEVity medicines},
author = {Shunhua Ding and Qingyu Lei and Wojciech Chrzanowski},
journal = {Biomedical Materials Science},
year = {2026},
doi = {10.1186/s44495-026-00006-1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging cell 2026
Open access · OA
Engineering Extracellular Vesicles for Anti-Aging Therapy: Mechanisms, Applications, and Perspectives.
medRxiv 2021
Preprint · OA
Single nuclei profiling identifies cell specific markers of skeletal muscle aging, sarcopenia and senescence
Aging and Disease 2025
Open access · CC-BY
Decoding Aging through iPSC Reprogramming: Advances and Challenges
Advanced Therapeutics 2026
Open access · CC-BY
Extracellular Vesicles: Biology, Intercellular Communication and Therapeutic Potential in Diabetes
Journal of Aging Research 2025
Open access · CC-BY
Modulating Ferroptosis in Aging: The Therapeutic Potential of Natural Products
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025
Open access · OA